Ocera Therapeutics, Inc. (NASDAQ:OCRX) registered a -70.73% decrease, still its new closing price is -65.89% up from the company’s 1 year high of 3.90.It posted -70.73% losses in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 4 stock analysts following this company have an average price target at $9.00, with individual PT in the $7.00-$11.00 range. The shares moved at $0.60, implying that brokerage firms see shares losing about -77.78% in twelve months time.

Ocera Therapeutics, Inc. (OCRX) SEC Form 4 News

The stock is getting much attention these days as insiders are adding shares while they posted a -71.43% fall year to date. A President and CEO at Ocera Therapeutics, Inc. (OCRX) acquired shares in a transaction closed on Wednesday December 07, 2016. Grais Linda S bought 7,000 shares in the company at $2.14 each and collected $14,001 in proceeds. Grais Linda S now owns 70,000 shares in the company after this transaction. A Chief Medical Officer in the company, Bukofzer Stan, disclosed a transaction on Thursday October 13, 2016 that ended up paying $6,001 from the purchase of 2,500 shares at $2.64 per share.

Ocera Therapeutics, Inc. (NASDAQ:OCRX) Upcoming Results on Tap

Ocera Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.31 in that period. Sales during the quarter are predicted to arrive at $0.

Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.32. The mean forecast was for $0 and $-0.35 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.33/share.

Ocera Therapeutics, Inc. (OCRX) Brokerage Update

Over the last six months and over the last three months, the shares of Ocera Therapeutics, Inc. (OCRX), have changed -76.92% and -70.73%, respectively.